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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease affecting 5.4 million people globally
and is predicated to affect over 100 million people worldwide by 2050 [1]. It is the most common
form of progressive cognitive decline. As originally described by Alois Alzheimer in 1907, AD
is associated with extracellular amyloid plaque formation and intracellular neurofibrillary
tangles in the brain regions involved in learning and memory processes [2]. A major problem
of the disease is, perhaps, altered proteolytic processing of the amyloid precursor protein (APP)
resulting in the production and aggregation of neurotoxic forms of Aβ. Amyloid plaques are
extracellular deposits of fibrils and amorphous aggregates of β-amyloid (Aβ). Compact
plaques have been considered to be associated with neuronal and synaptic loss, dystrophic
neurites, hypertrophic astrocytes, activated microglia cells, and various features of inflamma‐
tory processes. The intracellular neurofibrillary tangles consist of paired helical filaments
formed by the microtubule-associated protein tau that exhibits hyperphosphorylation and
oxidative modifications. Increasing lines of evidence have shown that visual impairment is
associated with the prevalence of AD [3]-[5].
Glaucoma is recognized as an age-related neurodegenerative disorder – optic neuropathy.
Being the second leading cause of blindness, it is estimated that glaucoma will affect more than
80 million people worldwide with at least 6 - 8 million individuals becoming bilaterally blind
by the year 2020 [6]. Comparing to normal population, the prevalence of glaucoma is about
2.5 times higher in AD patients [7]. In 2011, Nucci and co-workers reported that glaucoma
progression was associated with altered levels of Aβ and tau proteins in cerebral spinal fluid
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[8]. The intravitreous levels of Aβ1-42 are significantly decreased and that of tau are markedly
increased in glaucoma patients [9]. We propose that accumulation of Aβ and hyperphos‐
phorylated tau protein should be considered to be new pathological factors to propagate
neurodegeneration in glaucoma.
1.1. Amyloid precursor protein and functions
APP is a type I transmembrane protein with a single transmembrane domain, a large extrac‐
ellular ectodomain, and a short cytoplasmic tail [10]. The processing of APP to Aβ is an
important event in the pathogenesis of AD [11]. The processing is initiated by cleavage of APP
by α-secretase within the Aβ region, and by cleavage by β-secretase (BACE) at the amino
terminus of Aβ, leading to the secretion of large soluble ectodomains. In pathological situation,
if the carboxyl-terminal fragments is processed by γ-secretase resulting in the production of
Aβ, p3, and the APP intracellular domain (AICD). In humans, the APP gene is located on
chromosome 21 with three major isoforms (APP695, APP751 and APP770) arising from
alternative splicing [12]. APP is highly expressed in neurons where the protein is rapidly
transported down the axons to nerve terminus in the brain and retina [13].
As the processing of APP to Aβ is an important event in the pathogenesis of AD, great effort
has been devoted to understand biological functions of APP since its cloning in 1988 [10]. In
vitro and in vivo studies have shown important activities of APP in modulating neurite
outgrowth [14], synaptic activity [15]-[17], metal homeostasis [18], [19], synaptic transmission
[20] and synaptic adhesion at the neuromuscular junction [21]. In retina, APP plays a role in
retinogenesis. In APP knockout (KO) mice, differentiation of some inner retinal neurons,
specifically horizontal and amacrine cells are hampered in APP-KO mice during early
postnatal development[22]. However, normal numbers of horizontal cells and most types of
amacrine cells are found in adult APP-KO mice. The number is similar to adult C57/B6JxSV129
wild type control mice. APP is expressed in inner retina including horizontal, cone bipolar,
amacrine and ganglion cells in the APP-KO mice. Although APP is not required for gross
retinal structure or visual acuity in adult retina, it is required for the inner retinal function of
the rod and cone pathway [23].
1.2. Tau protein and functions
1.2.1. Tau protein
Tau protein is microtubule-associated protein that stabilizes microtubules and able to form
aggregation in pathological conditions. Tau is expressed from the gene known as microtubule-
associated protein tau (MAPT) on chromosome 17 at position 17q21. Tau is highly expressed
in neurons and is abundant in axons [24]. Hyperphosphorylated, insoluble, and filamentous
tau proteins were shown to be the main component of neurofibrillary tangles (NFTs), a
pathological hallmark of AD [24].
Tau binding to microtubules enables them to play a fundamental role in promoting microtu‐
bule assembly and stability; and in turn, affecting intra-neuronal transport of cargos. Detach‐
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ment of tau from microtubules leads to dysfunction of axonal transport and even retraction of
spines[25]. Apart from stabilizing microtubules, tau has a more versatile role in the central
nervous system (CNS). Tau regulates the process of neurite extension via its ability to stop
microtubule-severing proteins and its facilitative role on nerve growth factor signaling [26].
Tau interacts via its amino-terminal projection domain with the kinase Fyn (a proto-oncogene
tyrosine-protein kinase). Fyn phosphorylates the N-methyl-D-aspartate receptor (NMDAR) to
link NMDAR to synaptic excitotoxic downstream signaling [27]. Recent findings also reported
that Tau can modulate phospholipase C gamma [28], histone deacetylase-6 [29], and heat shock
proteins [30]. Tau also interacts with actin via acidic N-terminals, projecting from microtubules
for neurite outgrowth and stabilization during the brain development [31]. In tau knockout
mice, neurogenesis is severely reduced [32].
1.2.2. Multiple functions of tau in the retina
In the retina, tau not only regulates the cytoskeleton and axonal transport in retinal neurons,
but also affects accumulation of Aβ and cell survival signaling. The pivotal roles of tau in retinal
functions are summarized in Figure 1.
It has been found that tau is expressed in a gradient manner in retinal ganglion cells (RGC),
with higher levels in the terminal parts of axons of developing RGCs. Its localization at the
axon plays a role in proper axon development and survival of RGCs [33]. Exposure to okadaic
acid resulted in accumulation of phosphorylated tau, followed by distortion of the cytoskeleton
leading to growth cone collapse. Hence, tau has been implicated in the process of establishing
neuronal axon polarity [34]. Interruption in these transport mechanisms would cause the
accumulation of Aβ, which can propagate secondary degeneration. Studies based on Tg2576
transgenic mice showed that immunoreactivity of hyperphosphorylated tau was found to be
very close to that of Aβ in mouse retina [35].
Tau can be phosphorylated by cyclin-dependent kinase 5 (Cdk5), a proline-directed serine/
threonine kinase. Phosphorylation leads tau to dissociate from microtubules and affects its
stability. Cdk5 is highly expressed in neuronal axons and growth cones serving to promote
neurite outgrowth and migration[36]. To initiate its activation, Cdk5 requires interaction with
its activator subunit p35. Cdk5 has been implicated to phosphorylate various substrates to
regulate a diverse range of cellular processes in the CNS. Studies have shown that ephrin-A
signaling pathway can also lead to the activation of Cdk5. Ephrin-A regulates retinotectal
projection via receptor-mediated axon growth repulsion through a complex signaling cascade.
Fyn can activate Cdk5 to phosphorylate collapsin response mediator protein (CRMP2) to
reduce microtubule assembly[37]. Immunofluorescence studies have shown that activation of
Cdk5 occurs downstream of ephrin-A5 signaling to phosphorylate tau in the growth cones
and axons of RGCs. These findings suggest that phosphorylation of tau serves as another
means to which ephrin-A signaling can induce microtubule reorganization in RGC growth
cones[38].
Apart from Cdk5, tau has also been found to interact with calcium/calmodulin-dependent
protein kinase II (CaMKII) in the CaMKII-α-associated protein complex in chick retina.
Endogenous association of tau with CaMKII-α suggests that it is important in regulating
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cytoskeletal assembly in neurons. Through the phosphorylation of tau, microtubule assembly
may be inhibited; and hence, the cellular architecture is disrupted[39].
Abnormally aggregated tau inhibits the transportation of mitochondria by kinesin-like motors
towards the cell periphery of rat RGCs. Consequently, neurons with perturbation of mito‐
chondria and peroxisomes suffer from loss of energy production and accumulation of reactive
oxygen species (ROS). The anterograde transport of vesicles required for growth cones and
synaptic function is retarded. In addition, these neurons may be more vulnerable to oxidative
stress[40]. In the RGCs axons of P301S mutant mice, the projection domain of tau interacts with
the C-terminus of p150, the major component of the dynein-activator. The co-localization of
tau and p150 suggests that tau dysfunction can result in the mislocalization of dynactin in
axons, which can result in neurodegeneration[41].
2. Clinical manifestation of visual deficits in Alzheimer’s patients
Various visual deficits in AD have been reported since 1987 [42]. Cognitive visual changes
have been reported in patients in the early stages of AD [43], including difficulties in reading
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Figure 1. Schematic diagram summarizing the roles of tau in retinal functions. Tau stabilizes microtubules. Dislocation
of Tau from microtubules can result in growth cone collapse. Accumulation of β-amyloid (Aβ) is an example to trigger
phosphorylation of tau and hence detaches from microtubule. Apart from Aβ as a triggering factor, any stimulation of
signaling cascade of cdk5, ephrin-A receptor or calmodulin-dependent protein kinase II affecting phosphorylation of
tau can also modulate microtubules. Once tau leaves microtubules after phosphorylation, they can easily form aggre‐
gation, which can further impair axonal transport mediated by kinesin or dynein. Consequently, mitochondria in the
distal part of nerve, nerve terminus or spines cannot obtain protection from the cell body (soma) so that they are col‐
lapse and cannot produce energy. Neurodegeneration can unavoidably occur.
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and finding objects [44]-[46], depth perception [43] perceiving structure from motion [44], [46]-
[48], color recognition [44], [49], and impairment in spatial contrast sensitivity [47], [50].
Previously, these changes have been attributed to neuronal damage to the visual pathways in
the brain rather than the retina [51]. However, there are increasing lines of evidence showing
that specific AD like pathology (amyloid plaques and NFT) in the brain can be found in the
retina. In 2011, Koronyn-Hamaoui and co-workers [52] identified amyloid plaques in the
retinas from AD patients as well as patients in mild cognitive impairment.
Cross-sectional imaging of the retina using optical coherence tomography (OCT) has demon‐
strated a significant reduction of thickness in peripapillary retinal fiber layer (RFL) of patients
with early AD when compared with age-matched controls[53]-[57]. The thinning of RFL was
observed predominantly in the inferior and superior quadrants, which was consistent with
the inferior and superior visual field loss in AD patients[44], [54]. Reduction of the macular
thickness has also been reported in AD; and the total volume of the macula is inversely
correlated with the severity of the disease[55]. Changes in the optic nerve head have been
observed using confocal scanning laser ophthalmoscopy (cSLO). The observed changes
include reduced RFL thickness, neuroretinal rim volume and area, and increased cup-disc
ratio; suggesting an overall reduction in the number of optic nerve fibers passing through the
optic nerve head [58]. These in vivo findings are corroborated by the histopathological findings
of axonal degeneration in optic nerves, reduced thickness of RFL and a significant reduction
in the number of large diameter RGCs in the post-mortem AD retinas [59], [60].
According to the definitions of glaucoma published in 2002 by an international consensus
panel [61], glaucoma is thought to be present when at least one eye has typical defects both in
structural and functional aspects (optic disc damage and visual field loss, respectively) [62].
Characteristically, the damage indicates the death of RGC in the inner retina and loss of axons
in the optic nerve. This structural loss of the axons can be recognized clinically by ophthal‐
moscope or can be detected by imaging devices such as OCT and scanning laser polarimetry.
Besides NFL thinning, the similarities between the ocular effects of AD and glaucoma can be
observed in pattern electroretinogram (PERG) responses [63], [64], the type of cell loss (large
magnocellular RGC) and possibly the mechanisms for loss of RGC (apoptosis) [65], [66]. This
may explain the high incidence of glaucoma in AD patients [7], [67]. The involvement of Aβ
accumulation and hyperphosphorylated tau protein might be important causes of neurodegn‐
eration of RGCs in glaucoma.
3. Retinal degeneration in AD transgenic mice
Since there is a lack of postmortem human retinal samples from AD patients, progress of
investigating pathogenesis of retinal neurodegeneration in the AD eyes is slow. Much of
the  insights  have gained from specific  gene mutations  that  account  for  the  familial  AD
(FAD). The majority (30-40%) of FAD is resulted from autosomal dominant inheritance with
mutated genes encoding presenilin 1 (PS1) on the long arm of chromosome 14, presenilin
2 (PS2) on chromosome 1 and amyloid precursor protein (APP) on chromosome 21 [68].
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Depending on the number of genes they express, transgenic mice come in three varieties:
single  (APP,  PS1,  or  Tau),  double  (APP/PS1,  APP/Tau),  or  triple  transgenic  (APP/PS1/
Tau) [69]. Behavioral studies on AD transgenic mice showed that the mice were suffered
from visual dysfunction [70].
Multiple lines of AD transgenic mice have elicited AD-like pathological hallmarks in the retina
as disease progresses [69]. The over-expression of APP, the production of soluble Aβ, and
Aβ deposition will lead to formation of amyloid plaques that can induce cell death via the
apoptotic pathway [71]. Even before formation of plaques, oligomeric Aβ can induce synaptic
degeneration. Furthermore, Aβ plays a role in inducing hyperphosphorylation of tau, which
in turn affects the integrity of retinal cells and their synapses in inner nuclear layer (INL) [72].
It has been reported that over-expression of APP, Aβ and/or tau deposition, neuronal cell loss,
changes of retinal glial cell, and vascular changes occur in the retina of AD transgenic mice.
The changes of retinal histopathology documented in the AD transgenic mouse models are
summarized in Table 1.
3.1. Loss of retinal neurons in AD transgenic mice
In consistent with the findings in the retina of AD patient, reduced retinal thickness between
RGCL and ONL was detected in Tg2576 mice [73]. This indicates that there was a loss of either
the photoreceptor cells in the ONL (rod and cone cells) or neuronal cells in the inner retinal
layers (RGC, horizontal cells, bipolar cells or amacrine cells). In double transgenic mice strain
(APPswe/PS1M146L), a significant increase in the number of apoptotic cells in the RGCL was
detected by TUNEL staining as the animal grew from 7.8 months to 27 months [11]. By using
a different double transgenic mice strain (APPswe/PS1∆E9), there was significant increase of
TUNEL-positive cells in the RGCL when comparing with age-matched controls. Most recently,
direct visualization of apoptotic RGCs in the retina was reported in triple transgenic mouse
model of AD [74]. Using a fluorophore-labeled annexin V protein as a marker of apoptosis and
cSLO to detect the fluorescence, the triple transgenic mice displayed increased number of RGC
apoptosis compared with wild-type controls.
3.2. Over-expression of APP in the AD retina
Compared to the wild-type mice, a significant increase in immunoreactivity of APP in the
cytoplasm was detected in RGCL and INL of various transgenic mice [11], [73], [74]. In single
transgenic Tg2576 mice, over expressed APP was detected in the RGCL and INL of 14-month-
old mice [73], [75]. In double transgenic mice strain APPswe/PS1M146L, over-expression of APP
was age-dependent. In 27 months old mice, immunoreactivity of APP was detected not only
in the different layers of retina such as NFL, RGCL, inner plexiform layer (IPL), INL, outer
plexiform layer (OPL), outer segment (OS) and retinal pigment epithelium (RPE) but also in
the retinal vasculature [11]. By using different double transgenic strain- APPswe/PS1∆E9, APP
immunoreactivity was exhibited in the RGCL only at an intermediate age of 10.5 months. In
earlier time point (9 month-old animals), moderate immunoreactivity of APP was detected
only in the IPL and OPL not in the RGCL [11], [73], [76], [77].
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3.3. Deposition of Aβ in the retina and retinal vasculature
The deposition of Aß, derived from abnormal processing of APP was found in the retinas of
AD transgenic mice. In single transgenic Tg2576 mice, Aβ was found to deposit from RGCL
to INL or even at ONL. Aβ deposits and plaque like formation were detected by four different
monoclonal antibodies such as BAM01, 6E10, Aβ-40 and Aβ-42 as well as Congo red stain‐
ing[73], [76]. Retinal Aβ deposit has also been found in double transgenic mouse models
expressing APP/PS1.
Mutant genes Type/
Age
Neuronal
cell loss^
APP over-
expression
Aβ deposits Aβ-deposited
vasculature
P-tau
deposits
Ref.
APPswe,
(HuAPP695.
K670N, M671L)
Single/
14-
months
Yes +++
(GCL, INL)
+++ (GCL, IPL, INL,
OPL, ONL, RV)
+ (OS)
Yes ±
(GCL, IPL, INL,
OPL, ONL)
[73]
APPswe,
(HuAPP695.
K595N, M596L)
Single/
2-to18-months
n/a +++
(GCL, INL)
±
(GCL, RV)
Yes n/a [75]
APPswe, PS1∆E9 Double/
6-to 12-months
n/a ++
(IPL, OPL)
±
(GCL, INL, RV)
Yes n/a [75]
APPswe, PS1∆E9 Double/
10.5-months
Yes +++
(GCL)
±
(NFL,CV)
Yes n/a [11]
APPswe, PS1∆E9 Double/
12-to 19-months
No n/a *(IPL, OPL) n/a n/a [77]
APPswe, PS1M146L Double/
7.8 months
Yes +
(GCL, INL)
Yes n/a [11]
APPswe, PS1M146L Double/
27-months
Yes +++
(NFL,GCL,
IPL, INL, OPL,
OS, RPE, RV)
+++
(NFL, GCL)
+
(RV, CV)
Yes n/a [11]
TauP301S Single/
1- to 6-months
No n/a n/a n/a ±(IPL), with
paired helical
filament
formation
[78]
PS1M146V, APPswe,
and TauP301L
Triple/
10-to 22-
months
Yes n/a *Yes
(layers not specified)
n/a n/a [79]
n/a: not applicable; swe: Swedish mutation; P-tau: hyperphosphorylated tau; ^  neuronal cells in the inner retinal regions,
including INL and GCL; * plaques formation; NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer;
INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear layer; OS: outer segment; RPE: retinal pigment
epithelium; RV: retinal vasculature; CV: choroidal vasculature; +++ strong level; ++ moderate level; + weak level; +/-
present.
Table 1. Retinal changes in documented AD transgenic mouse models
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In double transgenic mice strain APPswe/PS1M146L, Aβ was found to deposit predominantly in
NFL and RGCL in aged mice of 27 months but not at young mice of 7.8 months. In another
double transgenic strain APPswe/PS1∆E9, similar Aβ deposition was detected in intermediate
age of 10.5 months[11]. In another subsequent study using transgenic mice APPswe/PS1∆E9,
Aβ plaques were found by thioflavin-S staining in plexiform layers; the size and the number
of plaques significantly increased with age from 12 months[77]. The transparent nature of the
eyes allows direct tracking and visualization of the Aβ signal has also been detected in the
retinal and choroidal vasculature. In single transgenic Tg2576 mice, Aβ was detected around
microvessels in RGCL[73], [76]. Both retinal and choroidal vascular Aβ deposits were reported
in aged (27 months) APPswe/PS1M146L transgenic mice and intermediate-aged (10.5 months)
APPswe/PS1∆E9 mice [11].
3.4. Deposition of hyperphosphorylated tau in the retina
Hyperphosphorylation of tau protein and subsequent deposition as neurofilbrillary tangles is
associated with AD. Tau inclusions have been observed in the brains as well as in the retinas
of Tg2576 and triple transgenic mice [79]. In single transgenic Tg2576 mice, hyperphosphory‐
lated tau was detected by antibody AT8 in various retinal layers from RGCL through to the
ONL. The hyperphosphorylated tau was found to be associated with Aβ depositions [73].
Another single transgenic expresses human P301S tau transgene, hyperphosphorylated tau
was found to deposit in the RNFL and aggregated into filamentous inclusions in RGCs starting
from 2-month-old mice [78]. Hyperphosphorylation and aggregation of tau were associated
in vivo with reduced axonal transport, both anterograde and retrograde, in the optic nerve of
this transgenic mice line [80].
3.5. Glial reaction in AD retina
Glial reactions, activated microglia and astrocytes, in the retina were detected in different kinds
of AD transgenic mice at various ages. In Tg2576 transgenic mice, significant infiltration of
microglial cells detected by iba-1 and the increased astrocytes activation detected by GFAP in
the inner retina were detected as early as 4-month-old mice [73]. In double transgenic APPswe/
PS1M146L mice, microglia was increased in an age-dependent manner, which was in parallel
with Aß deposits and TUNEL positive RGC in the GCL. The average percentage of cells in the
GCL surrounded by microglial cells increased significantly from 10% in 7.8-month-old to 50%
in 27-month-old APPswe/PS1M146L transgenic mice [11]. In another double transgenic APPswe/
PS1∆E9 mice, qualitative evaluation revealed greater immunoreactivity of microglia in 12 to 19
months old transgenic mice when compared to age-matched non-transgenic control[77].
4. β-Amyloid peptide and glaucoma
4.1. Aβ in animal models mimic glaucoma
In a rat model mimicking chronic ocular hypertension (COH) [81], Aβ has been reported to be
implicated in the development of RGC apoptosis in glaucoma. Increased intracellular Aβ in
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RGC detected by using Aβ antibody was co-localized with apoptotic RGC cells. Targeting
Aβ pathway in this experimental model, three different approaches were applied including:
(i) β-secretase inhibitor to reduce formation of Aβ; (ii) an anti-Aβ antibody to clear Aβ
deposition; and (iii) Congo red to inhibit aggregation of Aβ and neurotoxic effects of Aß.
Manipulating production of Aβ pathway, apoptosis of RGC was successfully reduced by
suppressing further Aβ aggregation and inhibiting the enzymatic activity of amyloidogenesis.
The combined treatment (triple therapy) was more effective than either single- or dual-agent
therapy in protecting RGC survival under COH. Increased expression of Aβ in the RGCL and
optic nerve was related to abnormal APP-splicing in the presence of elevated IOP in DBA/2J
glaucomatous mouse retinas [82] and mouse experimental COH model [83]. Increase of Aβ in
the retinal in COH has been found to be associated with activation of caspase-8 and caspase-3,
and caspase-3-mediated APP cleavage product (DeltaC-APP) in the RGCs under COH [65].
Application of exogenous Aβ peptide into the vitreous also induced significant RGC apoptosis
in rat retina [81].
4.2. Aβ-mediated mitochondrial dysfunction and glaucoma
There are some suggestions that Aβ peptides modulate Ca2+ level in mitochondria that may
alter the mitochondrial morphology and physiology [84]. For examples, elevated cytosolic
Ca2+ levels may enhance fragmentation of mitochondria. This can lead to the perturbation of
fission and fusion balance, which may eventually cause mitochondrial dysfunction [85].
Dysregulation of Ca2+ homeostasis may also disrupt downstream pathways of Ca2+-dependent
regulators monitoring mitochondrial dynamics [84], [86]. Consequently, synaptic dysfunction
may occur due to the failure of meeting the energy demand in neurons, particularly in axonal
and dendritic terminals [86]-[88].
Our eyes are energy demanding organs in which high density of mitochondria exist at the
optic nerve heads [89]. If one applies Aβ to the eyes, it may trigger mitochondrial dysfunctions
resulting in retinal degeneration. Intriguingly, in a glaucomatous model where cultured RGCs
were subjected to elevated hydrostatic pressure, fission of mitochondria was found to be
enhanced, together with morphological changes and bioenergetics dysfunction [90]. A clinical
study showed that mean mitochondrial respiratory activity was decreased by 21% in patients
with primary open-angle glaucoma compared with age-matched control subjects (p < 0.001)
[91]. In rabbit model of COH, daily tropical application of 5 μM mitochondria targeted cationic
plastoquinone derivative SkQ1 (10-(6’-plastoquinonyl) decyltriphenylphosphonium) showed
reduction in glaucomatous changes [92]. This hypothesis may be extended to one of the causes
in Aβ-induced RGC apoptosis in glaucoma.
5. TAU and glaucoma
5.1. Tau in the retina of glaucoma patient
In aged retina (49-87 year-old human), there is a positive correlation between age and number
of tau-positive RGCs. Diffuse immunoreactivity of tau was found in the INL, while aggregated
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tau was found within the cytoplasm of photoreceptor cells in patients older than 63-years-old
[93]. Total tau is present in the INL and IPL but much reduced in glaucomatous retina. On the
other hand, phosphorylated Tau (pTau) recognized by monoclonal antibody-AT8 is detected
in glaucomatous retina at the outer border of the INL and occasionally in the IPL. It has also
been found that pTau was localized in horizontal cells labeled by cell marker-parvalbumin
[94]. The distribution of tau in the normal aged (Fig. 2A) and glaucomatous retina (Fig. 2B) is
summarized in Figure 2. The decrease of total Tau and accumulation of pTau in the glaucom‐
atous retina support the hypothesis showing that glaucoma shares pathways with AD. This is
consistent with previous reports showing an increased incidence of primary open-angle
glaucoma among AD patients. Recent evidence also indicates that altered cerebrospinal fluid
(CSF) circulatory dynamics can reduce the clearance of both Aβ and tau. Altered CSF circula‐
tory dynamics can reduce clearance of neurotoxin along the optic nerve in the subarachnoid
space; leading to deposition of tau and other toxic molecules which ultimately result in
glaucoma progression[94].
A. Normal aged retina
RPE
ONL
INL
OPL
IPL
RGCL
NFL
B. Glaucomatous retina
Tau Tau
Tau
Tau
Tau
Tau Tau
Tau
Tau
Tau
pTau
pTau pTau
pTau
Figure 2. Diagram summarizing the literature reporting on the distribution of tau in the retina of normal people (A)
and glaucomatous patient (B). The background is a cross semi-thin section showing the layered structure of the retina.
Ovals labelled ‘Tau’ represent expression of total tau. Cloudy labelled ‘Tau’ represent tau aggregates. Sparckle labelled
‘pTau’ represent expression of abnormal phosphorylated tau. NFL: nerve fiber layer, RGCL: retinal ganglion cell layer,
IPL: inner plexiform layer, INL: inner nuclear layer, OPL: outer plexiform layer, ONL: outer nuclear layer, RPE: retinal pig‐
ment epithelium.
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5.2. Tau in animal models mimic glaucoma
In human glaucoma (chronic ocular hypertension), decreased total Tau and increased phos‐
phorylated tau (pTau) are reported when compared to the age control group [94]. In animal
models mimicking acute ocular hypertension, the loss of tau is evident even at earlier stages
when the outer layer of the retina is mostly intact [95]. Acute ocular hypertension was induced
for 1 hour by elevation of IOP to 120 mm Hg. The loss of tau proteins in the retina has been
shown to occur from as early as 4 hours to over 7 days after induction of acute ocular hyper‐
tension. Proteolysis of tau has been suggested contributing to the pathogenesis of neuronal
cell death, correlating with an increase in calcium, followed by activation of calpain. Calpain-
induced conversion of p35 to p25 and activation of cdk5 are also involved in the RGC loss.
There is no direct evidence about increase of pTau. However, it is indirectly evident by the up-
regulation of the relevant kinase, cdk5, and the regulatory protein, p35/p25. One justification
for the failure to detect pTau is that tau protein is cleaved by calpain before detection is possible
[95]. Another justification is that this acute elevation of ocular hypertension actually blocks the
retinal blood supply at 120 mmHg IOP. This is an ischemia/reperfusion model which may
cause neuronal cell hypoxia. Under hypoxic conditions, similar changes have also been
reported. In rat retinas treated with hypoxic conditions, it has been found that immunoreac‐
tivity of tau is almost completely lost in retinas within 5 hours; however, the proteolytic
products of tau remain detectable [96]. The changes of Tau proteins in the chronic ocular
hypertension model which mimic glaucoma over a relative long and slow degenerative period
deserves further evaluation.
6. Future therapy
Increasing lines of evidence have demonstrated common pathological findings in both AD and
glaucomatous retinal degeneration. Neuronal losses, inflammatory responses, accumulation
of Aβ and pTau deposition are important pathological factors found in the brain and the retina
[94], [97]. However, the correlation among Aβ deposits, pTau formation and the retinal
degeneration is limited to histological level. The pathological mechanisms have not been
comprehensively investigated. Questions like what are the mechanisms triggered by Aβ and
tau to cause retinal degeneration are still waiting for answers.
As part of the CNS, the similarity between the brain and the retina allows the exchange of
knowledge in terms of pathological mechanisms and therapeutic intervention. Mitochondrial
dysfunction discussed above is one of the pathophysiological changes in both AD and retinal
degeneration [3], [98]. The discovery of significant involvement of double-stranded RNA-
dependent protein kinase (PKR) in the apoptosis of neurons in postmortem AD brain and in
experimental studies is another good example [99]-[101]. Years after our report of the PKR in
AD, PKR has also been proved to play important roles in neuronal apoptosis of RGCs in
endoplasmic reticulum (ER) stress-induced retinal neuronal loss [102]. Neuroprotective agents
found from in vitro AD research can also be applied to eye research. Our Studies on wolfberry,
Lycium barbarum, an anti-aging herb, can be a good example. In primary neuronal culture,
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wolfberry can alleviate the Aβinduced degenerative process by promoting survival signals,
suppressing ER stress, reducing glutamate excitotoxicity [103]-[107]. In rat glaucoma model,
wolfberry shows its beneficial effects on the retina based on suppressing neurodestructive
factors, modulating the inflammatory responses [108], and up regulating the expression of
protective chaperone – crystallin [109]. The neuroprotective effects of wolfberry shared
between AD and glaucoma further strengthen our hypothesis that knowledge obtained from
the brain can be transferred to the study of the retina.
On the other hand, retina can be a promising platform to investigate the efficacy of any
potential drugs on different neuronal cells. In the study of rat chronic glaucomatous model,
immunotherapy with a potential agent such as β-secretase inhibitor, Congo Red or Aβ
antibody successfully reduced Aβ-induced RGC apoptosis by suppressing further Aβ
aggregation and inhibiting the enzymatic activity of amyloidogenesis [81]. In APPswe/PS1ΔE9
mice, following MOG45D-loaded dendritic cells immunization, Aβ−plaque burden in the
retinas was reduced as effective as that in the brain [52].
In a recent study using APPswe/PS1ΔE9 mice with five days of systemic administration of
curcumin,  the  results  showed that  there  is  a  age-dependent  correlation between plaque
deposition  in  the  retina  and the  brain,  and increased accumulations  over  the  course  of
disease  progression [52].  This  is  the  very first  prove that  Aβ plaques  in  the  retina  pre‐
cede the existence of brain plaques. The Aβ plaques can be detected as early as 2.5 months
of age in the retina but Aβ plaques in the brain exists at the age of 5 months, which is
about 2 months later [110]. Curcumin is a natural and safe fluorochrome that binds and
labels  Aβ  plaques  [111],  [112].  In  a  six-month  randomized,  placebo-controlled,  double-
blind,  pilot  clinical  trial  in AD patients,  there was no significant side effects even when
patients took curcumin at the dose of 4 g/day [113].
Early sign of AD symptoms in the brain can hardly be detected. With the use of curcumin,
retinal degeneration may be the most important site to be studied in early AD pathology.
Future development of high-resolution optical imaging for early AD diagnosis, prognosis
assessment and response to therapies can be achieved non-invasively through direct imaging
of the retina. Progression of therapy is possible to be visualized qualitatively in a sense that
one can monitor the changes of a particular neuronal cell [114], [115]. Quantitative examination
of the disease stages have been performed by assessing the ratio of apoptosis to necrosis using
fluorescence counts of respective dyes [74]. Even more, a high spatial resolution of images with
a high signal-to-noise ratio ranging from 3:1 to 10:1 can be achieved with the imaging of the
retina [114], [115]. The merits of non-invasive retinal imaging can provide investigators a solid
support for assessing pathological status as well as developing and refining therapeutic
strategies. Considering the potential of direct optical imaging of the retina, especially the Aβ
plaques deposition in the retina labeled by curcumin, retinal degeneration in early AD is the
window of monitoring disease progression as well as effectiveness of treatment.
With all the findings we pointed out in this review, we can formulate our working hypothesis
for researchers: increase in the level of Aβ or hyperphosphorylated tau protein may be the co-
pathological factors of glaucoma leading to progressive neurodegeneration in the retina.
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